KGF-1
An epithelium-specific fibroblast growth factor that signals through FGFR2b to protect and regenerate keratinocytes and mucosal surfaces.
KGF-1 (keratinocyte growth factor 1; FGF-7) is a member of the fibroblast growth factor family that signals exclusively through the FGFR2b splice variant found on epithelial cells, acting as a potent mitogen and cytoprotective factor for keratinocytes and mucosal epithelium. Uniquely paracrine, it is produced by stromal cells to maintain the integrity of adjacent epithelial layers and support mucosal healing. Its recombinant form, palifermin (Kepivance, Amgen), is FDA-approved to reduce severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy. Research interest also extends to wound healing, hair growth, and epithelial protection.
Class
Recombinant fibroblast growth factor (FGF-7 family growth factor protein)
Routes
Subcutaneous, Topical, Intravenous (clinical palifermin)
Category
Healing & Recovery
Researched benefits
What it's studied for
Prevention of oral mucositis
The core clinically validated effect: recombinant KGF-1 (palifermin) protects and regenerates the oral and gastrointestinal epithelium during cytotoxic therapy, reducing the incidence and duration of severe chemotherapy- and radiation-induced mucositis. This is the basis of its FDA approval.
Keratinocyte proliferation
By binding FGFR2b and activating RAS/MAPK and PI3K/Akt signaling, KGF-1 drives proliferation, migration, and differentiation of keratinocytes, supporting epithelial regeneration.
Mucosal repair and cytoprotection
KGF-1 protects mucosal surfaces from damage caused by cytotoxic therapies, a cytoprotective action that supports healing of the gastrointestinal epithelium where FGFR2b is highly expressed.
Wound healing
As a potent epithelial mitogen, KGF-1 is studied for accelerating re-epithelialization in wound healing contexts within preclinical and clinical literature.
Hair growth
KGF-1 is reported to extend the anagen (active growth) phase of the hair growth cycle, an area of research interest for hair-related applications.
Mechanism
How it works
KGF-1 binds FGFR2b, the keratinocyte growth factor receptor, which is expressed exclusively on epithelial cells. This receptor specificity gives KGF-1 tissue-selective action on epithelia without direct effects on mesenchymal tissue.
Receptor activation triggers the RAS/MAPK and PI3K/Akt signaling cascades, which promote keratinocyte proliferation, migration, and differentiation. In the hair follicle, this signaling extends the anagen phase of the growth cycle.
KGF-1 is uniquely paracrine: it is produced by stromal (mesenchymal) cells and acts on adjacent epithelial layers to maintain their integrity and support mucosal healing. This stromal-to-epithelial signaling underlies its role in protecting mucosal surfaces.
During cytotoxic chemotherapy and radiation, KGF-1 protects the gastrointestinal and oral epithelium from breakdown. Because FGFR2b is highly expressed on these mucosal surfaces, KGF-1 provides cytoprotection and accelerates repair, forming the mechanistic basis for palifermin's use in preventing severe mucositis.
Evidence
Research & clinical studies (1)
Palifermin for oral mucositis after intensive therapy for hematologic cancers
In a double-blind phase 3 randomized controlled trial of 212 patients, palifermin (recombinant human KGF-1) reduced the incidence of WHO grade 3-4 oral mucositis from 98% to 63% (p<0.001) and median mucositis duration from 9 to 6 days, with significant reductions in opioid analgesic use and total parenteral nutrition.
Safety
Side effects & considerations
Contraindications & cautions
- Active cancer or history of cancer
- Pregnancy or nursing
KGF-1 carries a moderate risk profile in research contexts. Because it is a potent epithelial mitogen, active cancer history is a key consideration given theoretical concerns about stimulating epithelial cell growth. Review contraindications and consult a qualified healthcare professional before use.
FAQ
KGF-1 — common questions
What is KGF-1?
KGF-1 (keratinocyte growth factor 1; FGF-7) is a member of the fibroblast growth factor family that signals exclusively through the FGFR2b splice variant on epithelial cells, where it acts as a potent mitogen and cytoprotective factor for keratinocytes and mucosal epithelial cells. It is uniquely paracrine, produced by stromal cells to maintain adjacent epithelial layer integrity and support mucosal healing.
What is KGF-1 primarily studied for?
Wound healing, hair growth, keratinocyte proliferation, mucosal repair, and epithelial protection.
What is palifermin and how does it relate to KGF-1?
Palifermin (Kepivance, Amgen) is recombinant human KGF-1. It is FDA-approved to prevent severe oral mucositis in patients with hematologic malignancies undergoing myelotoxic conditioning for stem cell transplant.
What does the research show about KGF-1?
In a double-blind phase 3 randomized controlled trial of 212 patients, palifermin reduced the incidence of WHO grade 3-4 oral mucositis from 98% to 63% (p<0.001) and cut median mucositis duration from 9 to 6 days, with significant reductions in opioid use and total parenteral nutrition, confirming KGF-1's epithelial tissue-protective and repair-promoting activity.
What are the side effects and contraindications of KGF-1?
Reported contraindications and considerations include active cancer history and pregnancy or nursing. Because KGF-1 is a potent epithelial mitogen, cancer history is a particular concern. This is educational information only; consult a qualified healthcare professional before use.
Is KGF-1 approved for cosmetic or skin use?
No. The KGF-1 evidence base is specific to chemotherapy-conditioning mucosal protection in oncology settings. Palifermin is not approved for cosmetic applications, general wound healing, or skin rejuvenation.
